This is one of the biggest peptide regulatory updates in years, and it's just the beginning. The FDA has officially initiated the first step to reverse its 2023 stance, removing 12 peptides Dihexa (also known as PNB 0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often quoted Dihexa 1401708 83 5 BGC70883 Biosynth Dihexa Peptide Therapy Memory & Cognition Beverly Hills